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options are available, including aggressive liver resec-
tion, transplantation, chemoembolisation, chemotherapy 
and hormonal therapy 1, 2）. The decision as to which 
treatment will benefit each individual patient is far 
from simple, and requires a multidisciplinary ap-
proach 3）. Selective internal radiation therapy （SIRT） 
is currently being used to target non-resectable hepat-
ic metastases with the aim of improving symptoms 
and prolonging survival 4）. We report our early results 
with SIRT for non-resectable liver metastases from 
INTRODUCTION
Liver metastases from neuroendocrine tumor （NET） 
represent a management dilemma, as many treatment 
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SUMMARY
PURPOSE：The aim of this study was to investigate changes in spleen size, the level of chromogranin A 
as a tumor marker, and the relationship between these two parameters before and 3 months after selective 
internal radiation therapy （SIRT） for non-resectable liver metastases from neuroendocrine tumor （NET）. 
Our first serious adverse event with this relatively new treatment is also discussed.
METHODS：A retrospective review of a prospective database identified patients with non-resectable liv-
er metastases from NET who underwent SIRT between 2003 and 2007. Patients who underwent CT scans 
before and 3 months after treatment were included. The patients were divided into two groups：those with 
and without a 20％ or more increase in splenic volume on the CT scans. The percentages of patients show-
ing a tumor marker response in the two groups were then compared
RESULTS：Fourteen patients were included in the present analysis. A tumor marker response was seen 
in 6 of 7 patients （85.7％） who showed an increase in splenic volume of＞20％, and in 3 of 7 patients （42.9
％） without an increase in splenic volume （p＝0.266）. There was one death as a result of oesophageal va-
riceal bleeding due to portal hypertension at 9 months after treatment.
CONCLUSION：Splenic enlargement after SIRT may be associated with tumor marker response, al-
though this could not be confirmed statistically in this study due to the small number of patients. Long-term 
splenomegaly and portal hypertension may be important complications of SIRT. This issue needs to be in-
vestigated further using a larger number of patients and longer follow-up.
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were included in the present analysis. Four patients 
were excluded because they had previously undergone 
splenectomy, and 9 patients did not undergo a CT scan 
at 3 months after SIRT.
Eight patients had an increase in splenic volume of
＞20％, while the other 8 did not. In the patients with 
an increase in splenic volume of＞20％, the mean 
splenic volume at the baseline was 226 mL （range 
92 mL−485 mL）. At 3 months after SIRT the mean 
splenic volume was 299 mL （range 111 mL−599 mL；
mean difference 75 mL, 95％ CI, 27 mL−118 mL, p＝
0.007）. For the other 8 patients, the mean splenic vol-
ume at the baseline was 289 mL （range 112 mL−
620 mL）, and at 3 months after SIRT it was 259 mL 
（range 110 mL−393 mL；mean difference 30 mL, 95％ 
CI, −40 mL−100 mL, p＝0.348） （Table 1）. Unfortu-
nately, 2 patients, one in each group, did not undergo 
repeat determination of the CgA level at 3 months af-
ter SIRT. Among the 7 patients with a splenic volume 
increase of＞20％, 6 （85.7％） showed a tumor marker 
response. Three （42.9％） of the 7 patients in the other 
group had a tumor marker response （p＝0.266） （Ta-
ble 2）.
One patient who died at 10 months after SIRT had a 
splenic size of 485 mL prior to treatment, and at 3 
months after treatment the splenic size was 599 mL 
（the largest size in the study group）. He remained 
well for 8 months, although multiple bone metastases 
were revealed by a pre-SIRT bone scan. He became 
jaundiced and his condition deteriorated with periph-
eral oedema, progressive ascites and weight loss. He 
was admitted to hospital at 9 months after SIRT with 
upper gastrointestinal bleeding and a duodenal ulcer, 
and oesophageal varices were noted at gastroscopy. He 
suffered further gastrointestinal bleeding, and repeat 
NET focusing particularly on changes in splenic vol-
ume and tumor marker response.
METHODS
We reviewed the records of all patients who had un-
dergone SIRT for unresectable liver metastases from 
NET in a pilot study. All patients who had undergone 
CT scans at the baseline prior to, and 3 months after, 
SIRT were included in the present analysis. Splenic 
volume was calculated using a digitizer Tablet （Kurta 
1s/one, Kurta Corporation, Phoenix, AZ）. By using the 
known scale on the CT images, the specific area of the 
spleen was calculated on each slice, and all the slices 
were summed to estimate the volume of the spleen. 
Serum tumor marker levels at the baseline and at 3 
months were also recorded. Chromogranin A （CgA） 
was used as the tumor marker, as this has been shown 
to be reliable for monitoring therapeutic outcome in 
patients with neuroendocrine tumors 5）.
Patients were divided into two groups：those in 
whom splenic volume increased≧20％, and those in 
whom it increased＜20％. Statistical analysis was per-
formed to assess any association between the change 
in splenic volume and a tumor marker response.
Statistical analyses were performed using SPSS v. 
12.0 for Windows （SPSS）. The paired sample t-test 
was used for comparison of continuous variables, and 
chi-squared test with Yates’s correction and Fisher’s 
exact test were used for categorical variables. Statisti-
cal significance was defined as p＜0.05.
RESULTS
A total of 29 patients with non-resectable liver me-
tastases from NET were identified. Sixteen patients 
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Table 1　 Splenic volume before and 3 months after SIRT in patients with neuroendocrine hepatic metastases, categorised 
into splenic volume increase of more than or less than 20％
Group Number of patients
Mean splenic volume
（mL） before SIRT 
（range） 
Mean splenic volume
（mL） 3 months after 
SIRT （range） 
Difference （mL）
（95％ confidence interval） 
＞20％ splenic volume 
increase
8 226 （92-485） 299 （111-599） 75 （27-118）　
＜20％ splenic volume 
increase
8 289 （112-620） 259 （110-393） 30 （−40-100） 
Splenic size after SIRT
largement after SIRT, and postulated that splenic en-
largement following SIRT and hepatic arterial infusion 
chemotherapy are due to portal hypertension caused 
by scarring within the liver as a consequence of radia-
tion and chemical hepatitis, respectively 14）.
In our small series, there was one serious adverse 
event that may have been related to SIRT. Although 
our results have insufficient statistical validity, they 
suggest that in patients who respond to treatment, 
SIRT does lead to an increase in splenic volume, indic-
ative of underlying portal hypertension, and its associ-
ated complications. A further study with a larger num-
ber of patients and a longer follow-up will be needed.
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